ClinicalTrials.gg
CompletedNCT02762981Updated Dec 6, 2022Results posted

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

A Phase 1/2 interventional study of Relacorilant with nab-paclitaxel in Solid Tumors, sponsored by Corcept Therapeutics. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-06.

Sponsored by Corcept Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Albumin-Bound Paclitaxel · Triple Negative Breast Neoplasms.

Enrollment
11th of 25
85 · median 64
Started
2016
the only one that year
Phase 1/2
2 of 25
1 open now
Registered
9th of 25
by date

Among the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms, this one is the 11th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1/2, and was the 9th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

7 of the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The structure for the study was a single arm, non-randomized, open- label, multicenter trial with no control group.

Read the detailed description

The study consisted of two segments to evaluate alternative dosing schedules of relacorilant administered at escalating dose levels. Segment I was to evaluate a continuous-dosing regimen and Segment II was to evaluate an intermittent-dosing regimen. Enrollment in Segment I and Segment II were mutually exclusive, and the two segments enrolled participants concurrently.

In Segment I continuous-dosing cohorts, participants received a single nab-paclitaxel lead-in infusion on Day 1 of Week -2 before Cycle 1, and oral relacorilant lead-in once-daily of Week -1 before Cycle 1. After the Data Review Committee review of data for 2 dose levels, the nab-paclitaxel lead-in was discontinued. The lead-in period was followed by oral relacorilant administered continuously once daily, in combination with nab-paclitaxel infusions on Days 1, 8, and 15 of each 28-day cycle. Segment 1 enrolled a total of 64 participants.

In Segment II intermittent-dosing cohorts, participants received a single relacorilant lead-in dose on Day -1 before Cycle 1, followed by oral relacorilant, administered intermittently the day before, the day of, and the day after nab-paclitaxel infusions on Days 1, 8, and 15 of each 28-day cycle. Segment II enrolled a total of 21 participants.

03

Conditions studied

  • Solid Tumors

Keywords

  • CORT125134
  • nab-paclitaxel
  • Triple-Negative Breast Cancer
  • Ovarian Epithelial Cancer
  • GR Antagonist
  • Glucocorticoid Receptor Antagonist
  • Pancreatic Cancer
  • Solid Tumors
  • Relacorilant
  • Abraxane
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with advanced or solid tumors who have disease progression after treatment with available therapies and for whom nab-paclitaxel treatment is appropriate.
  • Measurable or evaluable disease.
  • Up to 3 prior cytotoxic chemotherapeutics regimens or myelosuppressive therapies in the advanced setting.
  • (ECOG) performance status of 0 or 1.
  • For Part 2 Only: Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, or Triple Negative Breast Cancer with as defined by (RECIST) v1.1 in at least 1 lesion, that in the opinion of the Investigator is appropriate to treat with nab-paclitaxel.

Exclusion criteria

Exclusion Criteria:

  • Any major surgery within 4 weeks prior to the first dose of study drug.
  • Some protocol specified treatments prior to the first dose of study drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Relacorilant with nab-paclitaxel

    Participants will be treated with relacorilant in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.

    Drug: Relacorilant with nab-paclitaxel

Interventions

  • DrugRelacorilant with nab-paclitaxel

    Drug pages: Relacorilant · Albumin-Bound Paclitaxel

    Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.

    Also known as: Abraxane, Nanoparticle albumin-bound paclitaxel, CORT125134

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicity

    The Maximum Tolerated Dose and the development regimen of relacorilant with nab-paclitaxel was determined by the number of participants with dose-limiting toxicities as defined in the protocol.

    Time frame: Up to completion of Cycle 1 (up to 28 days)

Secondary outcomes

  1. Number of Participants With One or More Adverse Events Related to Treatment With Relacorilant

    Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: Up to 28 days after the last dose of study drug (Segment I: up to approximately 2.5 years, Segment II: up to approximately 1.5 years)

Other outcomes

  1. Objective Response Rate

    Objective response rate is defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as best response of complete response (CR) or partial response (PR) from the start of relacorilant or nab-paclitaxel, whichever is earliest, across all time points during study observation period (including both confirmed and unconfirmed responses).

    Time frame: Up to 512 days

  2. Clinical Benefit Rate

    Clinical benefit rate is defined as the participants who have achieved CR or PR (including both confirmed and unconfirmed responses), or stable disease for 16 weeks or greater.

    Time frame: Up to 512 days

  3. Duration of Response

    Duration of response (DOR) is defined as the date that criteria are met for CR or PR until the first date that progressive disease or death is objectively documented, whichever occurs first. Participants with no documentation of disease progression or death on-study are censored at the date of last available tumor assessment

    Time frame: From the time of response up to the last disease assessment (up to 512 days)

  4. Progression-free Survival

    Progression-free survival is defined as the time from date of first dose of relacorilant or nab-paclitaxel, whichever is earliest, to the date of documented disease progression per RECIST v1.1 or death for any cause, whichever occurs first. Participants with no documentation of disease progression or death on-study are censored at the date of last available tumor assessment.

    Time frame: Up to 512 days

  5. Overall Survival

    Overall survival is defined as the time from date of the first dose of relacorilant or nab paclitaxel, whichever is earliest, to the date of death for any cause. Participants with no documentation of death on-study are censored at the date at which they are last known to be alive.

    Time frame: Up to 512 days

  6. Best Response Rate in Participants With Tumor Glucocorticoid Receptor (GR) Above or Below the Median Overall Level

    Best response is defined by RECIST v1.1 as the best response recorded from the date of the first dose of relacorilant or nab-paclitaxel, whichever is earliest, across all time points during study observation period (including both confirmed and unconfirmed responses).

    Time frame: Up to 512 days

  7. Pharmacokinetics: Area Under the Concentration-time Curve From Zero to 24 Hours (AUC0-24) of Plasma Relacorilant

    Time frame: Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1

  8. Pharmacokinetics: AUC0-24 of Plasma Nab-Paclitaxel

    Time frame: Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1

  9. Pharmacokinetics: Maximum Concentration (Cmax) of Plasma Relacorilant

    Time frame: Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1

  10. Pharmacokinetics: Cmax of Plasma Nab-Paclitaxel

    Time frame: Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1

07

Results

Posted Dec 6, 2022

Participant flow

Participant flow — Overall Study
MilestoneSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
Started17407165
Completed00000
Not completed17407165
Withdrew: Adverse event23113
Withdrew: Physician decision01001
Withdrew: Disease progression11234101
Withdrew: Enrolled not treated15020
Withdrew: Other23100
Withdrew: Missing10000
Withdrew: Withdrawal by subject05130

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicity

The Maximum Tolerated Dose and the development regimen of relacorilant with nab-paclitaxel was determined by the number of participants with dose-limiting toxicities as defined in the protocol.

Time frame:
Up to completion of Cycle 1 (up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicity
ParticipantsSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
Number of Participants With Dose-limiting Toxicity08223
SecondaryNumber of Participants With One or More Adverse Events Related to Treatment With Relacorilant

Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
Up to 28 days after the last dose of study drug (Segment I: up to approximately 2.5 years, Segment II: up to approximately 1.5 years)
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events Related to Treatment With Relacorilant
ParticipantsSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
Number of Participants With One or More Adverse Events Related to Treatment With Relacorilant13245135
Other pre-specifiedObjective Response Rate

Objective response rate is defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as best response of complete response (CR) or partial response (PR) from the start of relacorilant or nab-paclitaxel, whichever is earliest, across all time points during study observation period (including both confirmed and unconfirmed responses).

Time frame:
Up to 512 days
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsSegment I: Continuous Dosing RegimensSegment II: Intermittent Dosing Regimens
Objective Response Rate72
Other pre-specifiedClinical Benefit Rate

Clinical benefit rate is defined as the participants who have achieved CR or PR (including both confirmed and unconfirmed responses), or stable disease for 16 weeks or greater.

Time frame:
Up to 512 days
Reported as:
Count of participants · Participants
Clinical Benefit Rate
ParticipantsSegment I: Continuous Dosing RegimensSegment II: Intermittent Dosing Regimens
Clinical Benefit Rate136
Other pre-specifiedDuration of Response

Duration of response (DOR) is defined as the date that criteria are met for CR or PR until the first date that progressive disease or death is objectively documented, whichever occurs first. Participants with no documentation of disease progression or death on-study are censored at the date of last available tumor assessment

Time frame:
From the time of response up to the last disease assessment (up to 512 days)
Reported as:
Median · months
Duration of Response
monthsSegment I: Continuous Dosing RegimensSegment II: Intermittent Dosing Regimens
Duration of Response9.7 (5.4 to 10.7)NA (0.95 to NA)
Other pre-specifiedProgression-free Survival

Progression-free survival is defined as the time from date of first dose of relacorilant or nab-paclitaxel, whichever is earliest, to the date of documented disease progression per RECIST v1.1 or death for any cause, whichever occurs first. Participants with no documentation of disease progression or death on-study are censored at the date of last available tumor assessment.

Time frame:
Up to 512 days
Reported as:
Median · Months
Progression-free Survival
MonthsSegment I: Continuous Dosing RegimensSegment II: Intermittent Dosing Regimens
Progression-free Survival2.8 (2.1 to 4.0)3.7 (2.9 to 16.2)
Other pre-specifiedOverall Survival

Overall survival is defined as the time from date of the first dose of relacorilant or nab paclitaxel, whichever is earliest, to the date of death for any cause. Participants with no documentation of death on-study are censored at the date at which they are last known to be alive.

Time frame:
Up to 512 days
Reported as:
Median · Months
Overall Survival
MonthsSegment I: Continuous Dosing RegimensSegment II: Intermittent Dosing Regimens
Overall Survival8.3 (5.2 to 10.9)16.5 (8.5 to NA)
Other pre-specifiedBest Response Rate in Participants With Tumor Glucocorticoid Receptor (GR) Above or Below the Median Overall Level

Best response is defined by RECIST v1.1 as the best response recorded from the date of the first dose of relacorilant or nab-paclitaxel, whichever is earliest, across all time points during study observation period (including both confirmed and unconfirmed responses).

Time frame:
Up to 512 days
Reported as:
Count of participants · Participants
Best Response Rate in Participants With Tumor Glucocorticoid Receptor (GR) Above or Below the Median Overall Level
ParticipantsGR H-score Above the Overall MedianGR H-score Below the Overall Median
Complete response10
Partial response31
Stable disease77
Progressive disease44
Missing or not evaluable14
Other pre-specifiedPharmacokinetics: Area Under the Concentration-time Curve From Zero to 24 Hours (AUC0-24) of Plasma Relacorilant
Time frame:
Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: Area Under the Concentration-time Curve From Zero to 24 Hours (AUC0-24) of Plasma Relacorilant
ng*h/mLSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
Pharmacokinetics: Area Under the Concentration-time Curve From Zero to 24 Hours (AUC0-24) of Plasma Relacorilant3380 ± 1393780 ± 1107480 ± 50.03300 ± 1047440 ± 146
Other pre-specifiedPharmacokinetics: AUC0-24 of Plasma Nab-Paclitaxel
Time frame:
Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: AUC0-24 of Plasma Nab-Paclitaxel
ng*h/mLSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
Pharmacokinetics: AUC0-24 of Plasma Nab-Paclitaxel2290 ± 48.53580 ± 67.53380 ± 12.73440 ± 62.85910 ± 73.7
Other pre-specifiedPharmacokinetics: Maximum Concentration (Cmax) of Plasma Relacorilant
Time frame:
Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Maximum Concentration (Cmax) of Plasma Relacorilant
ng/mLSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
Pharmacokinetics: Maximum Concentration (Cmax) of Plasma Relacorilant363 ± 100423 ± 88.8767 ± 47.4546 ± 89.4897 ± 55.2
Other pre-specifiedPharmacokinetics: Cmax of Plasma Nab-Paclitaxel
Time frame:
Segment I: before dosing and up to 24 hours after dosing on Cycle 1 Day 8; Segment II: before dosing and up to 24 hours after dosing on Cycle 1 Day 1
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Cmax of Plasma Nab-Paclitaxel
ng/mLSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
Pharmacokinetics: Cmax of Plasma Nab-Paclitaxel1810 ± 71.02660 ± 69.91560 ± 79.32600 ± 70.03070 ± 41.5

Adverse events

Collected over Up to 28 days after the last dose of study drug (Segment I: up to approximately 2.5 years, Segment II: up to approximately 1.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Segment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing Regimen12/14 (85.7%)6/14 (42.9%)13/14 (92.9%)
Segment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing Regimen19/34 (55.9%)18/34 (52.9%)31/34 (91.2%)
Segment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing Regimen5/6 (83.3%)5/6 (83.3%)6/6 (100%)
Segment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing Regimen4/14 (28.6%)8/14 (57.1%)14/14 (100%)
Segment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen4/5 (80%)3/5 (60%)5/5 (100%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
UrosepsisInfections and infestations0/140/340/60/141/5
Pleural effusionRespiratory, thoracic and mediastinal disorders2/140/341/61/141/5
NeutropeniaBlood and lymphatic system disorders0/142/340/60/141/5
Atrial fibrillationCardiac disorders2/140/340/60/141/5
VomitingGastrointestinal disorders0/141/341/62/140/5
PneumoniaInfections and infestations0/141/341/60/140/5
Corneal infectionInfections and infestations0/140/341/60/140/5
EmpyemaInfections and infestations0/140/341/60/140/5
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/141/341/60/140/5
Febrile neutropeniaBlood and lymphatic system disorders0/141/341/60/140/5
Most frequent other events
Showing 10 of 137
Most frequent other events
EventSegment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing Regimen
FatigueGeneral disorders5/1416/346/68/144/5
Neuropathy peripheralNervous system disorders3/147/345/63/143/5
NeutropeniaBlood and lymphatic system disorders1/149/341/65/144/5
NauseaGastrointestinal disorders7/1413/343/610/142/5
StomatitisGastrointestinal disorders1/144/344/64/140/5
Decreased appetiteMetabolism and nutrition disorders2/147/344/62/141/5
Nail disorderSkin and subcutaneous tissue disorders2/144/344/67/142/5
Skin hyperpigmentationSkin and subcutaneous tissue disorders1/145/344/67/142/5
CoughRespiratory, thoracic and mediastinal disorders2/143/344/65/141/5
Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders2/144/344/61/140/5

Baseline characteristics

All enrolled participants who received at least 1 dose of relacorilant. The Statistical Report specified summarization of Baseline Characteristic results by Segment I and Segment II.

Age, Continuous
Age, Continuous(years)Segment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing RegimenTotal
Mean57.0 ± 10.6060.6 ± 12.8156.8 ± 18.5159.6 ± 12.0264.8 ± 10.2159.7 ± 12.47
Sex: Female, Male
Sex: Female, Male(Participants)Segment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing RegimenTotal
Female920414350
Male51420223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Segment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing RegimenTotal
Hispanic or Latino132208
Not Hispanic or Latino1331412565
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Segment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing RegimenTotal
American Indian or Alaska Native000000
Asian001315
Native Hawaiian or Other Pacific Islander000000
Black or African American210126
White123149258
More than one race000000
Unknown or Not Reported021104
Region of Enrollment
Region of Enrollment(participants)Segment I: Relacorilant 100 mg + Nab-paclitaxel 60 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 100 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment I: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Continuous Dosing RegimenSegment II: Relacorilant 150 mg + Nab-paclitaxel 80 mg/m^2 Intermittent Dosing RegimenSegment II: Relacorilant 200 mg + Nab-paclitaxel 100 mg/m^2 Intermittent Dosing RegimenTotal
United States1434614573
08

Study locations

4 sites
  • 038
    Scottsdale, Arizona 85258, United States
  • 014
    San Francisco, California 94143, United States
  • 001
    Chicago, Illinois 60637, United States
  • 013
    Ogden, Utah 84403, United States
09

References and documents

Publications

  • Pivonello R, Munster PN, Terzolo M, Ferrigno R, Simeoli C, Puglisi S, Bali U, Moraitis AG. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Front Endocrinol (Lausanne). 2022 Jan 4;12:793262. doi: 10.3389/fendo.2021.793262. eCollection 2021. PubMed 35058882 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in May 2020, 47 months.

Results were first posted in Dec 2022, 2 years 6 months after primary completion.

Of 70 industry-sponsored phase 1/2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 77. This study's 47 months is below that.

Counting every sponsor, half of 118 studies reached it within 56 months; a quarter within 43 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2016
First posted
May 5, 2016
StartActual
May 23, 2016
Primary completionActual
May 12, 2020
CompletionActual
Sep 12, 2020
Results first posted
Dec 6, 2022
Last update
Dec 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02762981
Responsible party
Sponsor
First posted
May 5, 2016
Start date
May 23, 2016
Primary completion
May 12, 2020
Completion
Sep 12, 2020
Results posted
Dec 6, 2022
Last update
Dec 6, 2022

Study contacts

Medical Monitor
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relacorilant · Albumin-Bound Paclitaxel

Start the discussion